Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cidara Therapeutics, Inc. (CDTX : NSDQ)
 
 • Company Description   
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.

Number of Employees: 38

 
 • Price / Volume Information   
Yesterday's Closing Price: $50.45 Daily Weekly Monthly
20 Day Moving Average: 1,331,251 shares
Shares Outstanding: 20.16 (millions)
Market Capitalization: $1,017.26 (millions)
Beta: 1.14
52 Week High: $56.83
52 Week Low: $10.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 92.78% 87.00%
12 Week 152.25% 118.66%
Year To Date 87.69% 77.32%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6310 NANCY RIDGE DRIVE SUITE 101
-
SAN DIEGO,CA 92121
USA		 ph: 858-752-6170
fax: -		 britchie@lifesciadvisors.com http://www.cidara.com
 
 • General Corporate Information   
Officers
Jeffrey Stein - President and Chief Executive Officer
Daniel D. Burgess - Chairman
Frank Karbe - Chief Financial Officer
Bonnie Bassler - Directors
Carin Canale-Theakston - Directors

Peer Information
Cidara Therapeutics, Inc. (CORR.)
Cidara Therapeutics, Inc. (RSPI)
Cidara Therapeutics, Inc. (CGXP)
Cidara Therapeutics, Inc. (BGEN)
Cidara Therapeutics, Inc. (GTBP)
Cidara Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 171757206
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 20.16
Most Recent Split Date: 4.00 (0.05:1)
Beta: 1.14
Market Capitalization: $1,017.26 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-7.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.35
Price/Cash Flow: -
Price / Sales: 26.04
EPS Growth
vs. Year Ago Period: 27.19%
vs. Previous Quarter: 69.14%
Sales Growth
vs. Year Ago Period: -96.03%
vs. Previous Quarter: -96.43%
ROE
06/30/25 - -
03/31/25 - -73.04
12/31/24 - -89.32
ROA
06/30/25 - -
03/31/25 - -54.28
12/31/24 - -58.06
Current Ratio
06/30/25 - -
03/31/25 - 3.87
12/31/24 - 4.25
Quick Ratio
06/30/25 - -
03/31/25 - 3.87
12/31/24 - 4.25
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -61,454.97
12/31/24 - -13,356.16
Book Value
06/30/25 - -
03/31/25 - 11.60
12/31/24 - 14.92
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©